Literature DB >> 20944073

Langerhans cells are not required for graft-versus-host disease.

Hongmei Li1, Daniel H Kaplan, Catherine Matte-Martone, Hung Sheng Tan, Srividhya Venkatesan, Kody Johnson, Anthony J Demetris, Jennifer McNiff, Mark J Shlomchik, Warren D Shlomchik.   

Abstract

Graft-versus-host disease (GVHD) is initiated and maintained by antigen-presenting cells (APCs) that prime alloreactive donor T cells. APCs are therefore attractive targets for GVHD prevention and treatment. APCs are diverse in phenotype and function, making understanding how APC subsets contribute to GVHD necessary for the development of APC-targeted therapies. Langerhans cells (LCs) have been shown to be sufficient to initiate skin GVHD in a major histocompatibility complex-mismatched model; however, their role when other host APC subsets are intact is unknown. To address this question, we used mice genetically engineered to be deficient in LCs by virtue of expression of diphtheria toxin A under the control of a BAC (bacterial artificial chromosome) transgenic hu-man Langerin locus. Neither CD8- nor CD4-mediated GVHD was diminished in recipients lacking LCs. Similarly, CD8- and CD4-mediated GVHD, including that in the skin, was unaffected if bone marrow came from donors that could not generate LCs, even though donor LCs engrafted in control mice. Engraftment of donor LCs after irradiation in wild-type hosts required donor T cells, with immunofluorescence revealing patches of donor and residual host LCs. Surprisingly, donor LC engraftment in Langerin-diphtheria toxin A (DTA) transgenic hosts was independent of donor T cells, suggesting that a Langerin(+) cell regulates repopulation of the LC compartment.

Entities:  

Mesh:

Year:  2010        PMID: 20944073      PMCID: PMC3031488          DOI: 10.1182/blood-2010-07-299073

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  54 in total

1.  Host-derived Langerhans cells persist after MHC-matched allografting independent of donor T cells and critically influence the alloresponses mediated by donor lymphocyte infusions.

Authors:  Nadira Durakovic; Karl B Bezak; Mario Skarica; Vedran Radojcic; Ephraim J Fuchs; George F Murphy; Leo Luznik
Journal:  J Immunol       Date:  2006-10-01       Impact factor: 5.422

2.  Prevention of acute graft-versus-host disease by blocking T-cell entry to secondary lymphoid organs.

Authors:  Andreas Beilhack; Stephan Schulz; Jeanette Baker; Georg F Beilhack; Ryosei Nishimura; Enosh M Baker; Gilad Landan; Edward I Herman; Eugene C Butcher; Christopher H Contag; Robert S Negrin
Journal:  Blood       Date:  2007-11-07       Impact factor: 22.113

3.  Inflammatory murine skin responses to UV-B light are partially dependent on endothelin-1 and mast cells.

Authors:  Martin Metz; Verena Lammel; Bernhard F Gibbs; Marcus Maurer
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

4.  In vivo ablation of CD11c-positive dendritic cells increases susceptibility to herpes simplex virus type 1 infection and diminishes NK and T-cell responses.

Authors:  Sadik H Kassim; Naveen K Rajasagi; Xiangyi Zhao; Robert Chervenak; Stephen R Jennings
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

Review 5.  Graft-versus-host disease.

Authors:  Warren D Shlomchik
Journal:  Nat Rev Immunol       Date:  2007-05       Impact factor: 53.106

6.  Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells.

Authors:  Britt E Anderson; Patricia A Taylor; Jennifer M McNiff; Dhanpat Jain; Anthony J Demetris; Angela Panoskaltsis-Mortari; Ann Ager; Bruce R Blazar; Warren D Shlomchik; Mark J Shlomchik
Journal:  Blood       Date:  2008-02-19       Impact factor: 22.113

7.  Organ-derived dendritic cells have differential effects on alloreactive T cells.

Authors:  Theo D Kim; Theis H Terwey; Johannes L Zakrzewski; David Suh; Adam A Kochman; Megan E Chen; Chris G King; Chiara Borsotti; Jeremy Grubin; Odette M Smith; Glenn Heller; Chen Liu; George F Murphy; Onder Alpdogan; Marcel R M van den Brink
Journal:  Blood       Date:  2008-01-04       Impact factor: 22.113

8.  Autocrine/paracrine TGFbeta1 is required for the development of epidermal Langerhans cells.

Authors:  Daniel H Kaplan; Ming O Li; Matthew C Jenison; Warren D Shlomchik; Richard A Flavell; Mark J Shlomchik
Journal:  J Exp Med       Date:  2007-10-15       Impact factor: 14.307

9.  Identification of a novel population of Langerin+ dendritic cells.

Authors:  Laura S Bursch; Liangchun Wang; Botond Igyarto; Adrien Kissenpfennig; Bernard Malissen; Daniel H Kaplan; Kristin A Hogquist
Journal:  J Exp Med       Date:  2007-12-17       Impact factor: 14.307

10.  The dermis contains langerin+ dendritic cells that develop and function independently of epidermal Langerhans cells.

Authors:  Lionel Franz Poulin; Sandrine Henri; Béatrice de Bovis; Elisabeth Devilard; Adrien Kissenpfennig; Bernard Malissen
Journal:  J Exp Med       Date:  2007-12-17       Impact factor: 14.307

View more
  23 in total

Review 1.  Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity.

Authors:  Elizabeth O Stenger; Hēth R Turnquist; Markus Y Mapara; Angus W Thomson
Journal:  Blood       Date:  2012-03-07       Impact factor: 22.113

2.  Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic-derived antigen-presenting cells.

Authors:  Tomomi Toubai; Isao Tawara; Yaping Sun; Chen Liu; Evelyn Nieves; Rebecca Evers; Thea Friedman; Robert Korngold; Pavan Reddy
Journal:  Blood       Date:  2011-11-18       Impact factor: 22.113

3.  Epidermal Langerhans cells tune skin reactivity to contact allergens.

Authors:  Mark C Udey
Journal:  J Clin Invest       Date:  2012-04-23       Impact factor: 14.808

4.  Alternative mechanisms that mediate graft-versus-host disease in allogeneic hematopoietic cell transplants.

Authors:  James W Young
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

5.  Profound depletion of host conventional dendritic cells, plasmacytoid dendritic cells, and B cells does not prevent graft-versus-host disease induction.

Authors:  Hongmei Li; Anthony J Demetris; Jennifer McNiff; Catherine Matte-Martone; Hung Sheng Tan; David M Rothstein; Fadi G Lakkis; Warren D Shlomchik
Journal:  J Immunol       Date:  2012-03-14       Impact factor: 5.422

Review 6.  Acute graft-versus-host disease: a bench-to-bedside update.

Authors:  Shernan G Holtan; Marcelo Pasquini; Daniel J Weisdorf
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

7.  In vivo dynamics of T cells and their interactions with dendritic cells in mouse cutaneous graft-versus-host disease.

Authors:  Sarah Morin-Zorman; Christian Wysocki; Jieqing Zhu; Hongmei Li; Sylvain Zorman; Catherine Matte-Martone; Edwina Kisanga; Jennifer McNiff; Dhanpat Jain; David Gonzalez; David M Rothstein; Fadi G Lakkis; Ann Haberman; Warren D Shlomchik
Journal:  Blood Adv       Date:  2019-07-23

8.  A repertoire-independent and cell-intrinsic defect in murine GVHD induction by effector memory T cells.

Authors:  Kathryn W Juchem; Britt E Anderson; Cuiling Zhang; Jennifer M McNiff; Anthony J Demetris; Donna L Farber; Andrew J Caton; Warren D Shlomchik; Mark J Shlomchik
Journal:  Blood       Date:  2011-07-18       Impact factor: 22.113

9.  Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution.

Authors:  Ning Li; Catherine Matte-Martone; Hong Zheng; Weiguo Cui; Srividhya Venkatesan; Hung Sheng Tan; Jennifer McNiff; Anthony J Demetris; Derry Roopenian; Susan Kaech; Warren D Shlomchik
Journal:  Blood       Date:  2011-09-13       Impact factor: 22.113

10.  Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease.

Authors:  Motoko Koyama; Rachel D Kuns; Stuart D Olver; Neil C Raffelt; Yana A Wilson; Alistair L J Don; Katie E Lineburg; Melody Cheong; Renee J Robb; Kate A Markey; Antiopi Varelias; Bernard Malissen; Günter J Hämmerling; Andrew D Clouston; Christian R Engwerda; Purnima Bhat; Kelli P A MacDonald; Geoffrey R Hill
Journal:  Nat Med       Date:  2011-11-29       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.